Citigroup
ONC

Citigroup’s BeOne Medicines Ltd ONC Stock Holding History

Citigroup’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.03M Buy
10,188
+4,590
+82% +$1.49M ﹤0.01% 2370
2025
Q4 		$1.7M Sell
5,598
-871
-13% -$285K ﹤0.01% 2769
2025
Q3 		$2.2M Buy
6,469
+1,720
+36% +$522K ﹤0.01% 2594
2025
Q2 		$1.15M Sell
4,749
-11,070
-70% -$2.71M ﹤0.01% 3092
2025
Q1 		$4.31M Sell
15,819
-4,853
-23% -$1.13M ﹤0.01% 2033
2024
Q4 		$3.82M Sell
20,672
-5,640
-21% -$1.15M ﹤0.01% 2229
2024
Q3 		$5.91M Buy
26,312
+5,410
+26% +$973K ﹤0.01% 1717
2024
Q2 		$2.98M Buy
20,902
+12,701
+155% +$1.96M ﹤0.01% 2022
2024
Q1 		$1.28M Buy
8,201
+2,934
+56% +$472K ﹤0.01% 2828
2023
Q4 		$950K Buy
5,267
+2,508
+91% +$454K ﹤0.01% 2863
2023
Q3 		$496K Sell
2,759
-495
-15% -$97.9K ﹤0.01% 3067
2023
Q2 		$580K Buy
3,254
+491
+18% +$113K ﹤0.01% 3264
2023
Q1 		$596K Buy
2,763
+391
+16% +$93.8K ﹤0.01% 2994
2022
Q4 		$522K Sell
2,372
-7,525
-76% -$1.38M ﹤0.01% 3137
2022
Q3 		$1.33M Sell
9,897
-6,999
-41% -$1.2M ﹤0.01% 2480
2022
Q2 		$2.73M Sell
16,896
-1,110
-6% -$173K ﹤0.01% 1893
2022
Q1 		$3.4M Sell
18,006
-9,619
-35% -$2.04M ﹤0.01% 1923
2021
Q4 		$7.49M Buy
27,625
+2,269
+9% +$766K ﹤0.01% 1578
2021
Q3 		$9.21M Buy
25,356
+87
+0.3% +$28.4K 0.01% 1465
2021
Q2 		$8.67M Sell
25,269
-4,229
-14% -$1.4M 0.01% 1516
2021
Q1 		$10.3M Sell
29,498
-5,588
-16% -$1.85M 0.01% 1353
2020
Q4 		$9.06M Buy
35,086
+17,136
+95% +$4.72M 0.01% 1644
2020
Q3 		$5.14M Sell
17,950
-515
-3% -$121K ﹤0.01% 1866
2020
Q2 		$3.48M Buy
18,465
+145
+0.8% +$23.6K ﹤0.01% 2212
2020
Q1 		$2.26M Sell
18,320
-22,618
-55% -$3.54M ﹤0.01% 2373
2019
Q4 		$6.79M Sell
40,938
-75,857
-65% -$12.6M ﹤0.01% 1776
2019
Q3 		$14.3M Buy
116,795
+64,982
+125% +$8.63M 0.01% 1147
2019
Q2 		$6.42M Sell
51,813
-19,273
-27% -$2.45M 0.01% 1763
2019
Q1 		$9.38M Sell
71,086
-17,505
-20% -$2.36M 0.01% 1311
2018
Q4 		$12.4M Sell
88,591
-38,510
-30% -$5.11M 0.01% 1117
2018
Q3 		$21.9M Buy
127,101
+2,298
+2% +$386K 0.02% 791
2018
Q2 		$19.2M Sell
124,803
-1,067
-0.8% -$190K 0.02% 836
2018
Q1 		$21.1M Sell
125,870
-697
-0.6% -$94.4K 0.02% 749
2017
Q4 		$12.4M Buy
126,567
+58,930
+87% +$5.39M 0.01% 1135
2017
Q3 		$7M Buy
67,637
+66,803
+8,010% +$4.98M 0.01% 1483
2017
Q2 		$38K Sell
834
-327
-28% -$12.9K ﹤0.01% 5970
2017
Q1 		$43K Buy
1,161
+490
+73% +$17.9K ﹤0.01% 5798
2016
Q4 		$20K Buy
+671
New +$21.1K ﹤0.01% 6530
2016
Q2 		– Sell
-2
Closed – – 7493
2016
Q1 		$0 Buy
+2
New +$57 ﹤0.01% 7815

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citigroup's ONC Position: Q1 2026 in Review

Citigroup increased its BeOne Medicines Ltd (ONC) stake by 82% in Q1 2026, buying an estimated $1.49M and bringing the position to 10,188 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

Citigroup first reported a position in ONC in Q1 2016 and has held it in 39 quarters since. The position peaked at $21.9M in Q3 2018. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Citigroup held 10,188 shares of BeOne Medicines Ltd worth $3.03M as of Q1 2026.
  • Citigroup bought 4,590 BeOne Medicines Ltd shares in Q1 2026, an estimated $1.49M.
  • BeOne Medicines Ltd made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2370 holding.
  • Citigroup first reported a position in BeOne Medicines Ltd in Q1 2016 and has held it in 39 quarters since.
  • Citigroup's BeOne Medicines Ltd position peaked at $21.9M in Q3 2018.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.